Director

Nancy Miller-Rich

Director·4D Molecular Therapeutics, Inc.

About

Nancy Miller-Rich has served as a member of the 4DMT board of directors since November 2020. She has served as a consultant and advisor to various pharmaceutical and biotechnology companies since September 2017.

Previously, Ms. Miller-Rich served in a number of leadership roles at Merck & Co., Inc. and, prior to the merger of the two companies, at Schering-Plough Corporation, including most recently as Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from November 2013 to September 2017 and as Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from January 2007 to November 2013. Prior to joining Schering-Plough in 1990, she served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc.

Ms. Miller-Rich received her undergraduate degree in Business Administration, Marketing, from Ithaca College in 1981.

Since 2020
Age 67
Tenure 6 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director SM Shawn Cline Tomasello, MBA Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Director 2020–present Current role
Merck & Co., Inc. / Schering-Plough Corporation Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support 2013-2017 From November 2013 to September 2017 (most recent role).
Schering-Plough Corporation Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development 2007-2013 From January 2007 to November 2013; joined Schering-Plough in 1990.
Sandoz Pharmaceuticals Commercial and marketing roles Variety of commercial and marketing roles before 1990.
Sterling Drug, Inc. Commercial and marketing roles Variety of commercial and marketing roles before 1990.

External roles

Organization Role Dates
Aldeyra Therapeutics, Inc. Director
Intercept Pharmaceuticals, Inc. Director 2018-2023
Kadmon Holdings, Inc. Director 2020-2021
Attralus, Inc. Director
BioTheryX Director 2021-2023

Related

Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo